| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | -100.0% |
| R&D Expense | $65.8M | +4.4% | +57.1% |
| SG&A Expense | $12.6M | -3.8% | -17.7% |
| Operating Income | -$78.4M | -3.0% | -37.9% |
| Net Income | -$73.9M | -3.9% | -42.4% |
| EPS (Basic) | -$3.36 | -1.5% | -22.2% |
| EPS (Diluted) | -$3.36 |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $149.5M | -5.0% | -11.3% |
| Current Assets | $273.8M | -10.7% | -23.9% |
| Total Assets | $396.4M | -12.5% | -4.8% |
| Current Liabilities | $52.9M | +8.8% | +60.9% |
| Total Liabilities | $52.9M | +8.8% | +57.4% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$172.7M | — | — |
| Capital Expenditures | $56K | — | — |
| Investing Cash Flow | $17.2M | — | — |
| Financing Cash Flow | $89.7M | — | — |
| Free Cash Flow | -$172.8M | — | — |
| -22.2% |
| $343.5M |
| -15.0% |
| -10.2% |